All AbMole products are for research use only, cannot be used for human consumption.
SBI-115 is a TGR5 (GPCR19) antagonist, it decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5. SBI-115 inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes.
| Molecular Weight | 340.78 |
| Formula | C14H13ClN2O4S |
| CAS Number | 882366-16-7 |
| Solubility (25°C) | DMSO ≥ 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related GPCR19/TGR5 Products |
|---|
| Ursodeoxycholic acid sodium
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. |
| SB756050
SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment. |
| Deoxycholic acid sodium salt
Deoxycholic acid sodium salt is a bile acid and a by-product of intestinal metabolism, Deoxycholic acid sodium salt can activate the G protein-coupled bile acid receptor TGR5. |
| INT-777
INT-777 is a potent TGR5 agonist with EC50 of 0.82 μM. |
| BAR 502
BAR502 is a dual agonist of FXR and GPBAR1 with IC50 values of 2 μM and 0.4 μM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
